Get the Stockscreener App
2.03
0.49%
-0.01
After Hours:
2.04
0.01
+0.49%
Kiora Pharmaceuticals Inc stock is traded at $2.03, with a volume of 21,295.
It is down -0.49% in the last 24 hours and down -4.25% over the past month.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$2.04
Open:
$2.02
24h Volume:
21,295
Relative Volume:
0.45
Market Cap:
$7.47M
Revenue:
-
Net Income/Loss:
$2.81M
P/E Ratio:
-0.1415
EPS:
-14.3497
Net Cash Flow:
$7.14M
1W Performance:
-3.33%
1M Performance:
-4.25%
6M Performance:
-24.25%
1Y Performance:
-35.96%
1-Day Range:
$1.993
$2.0615
1-Week Range:
$1.98
$2.185
52-Week Range:
$1.7645
$4.18
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals Inc
Sector
Industry
Phone
858-224-9600
Address
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.03 | 7.50M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kiora Pharmaceuticals Inc Stock (KPRX) Latest News
KPRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Fear: Can Kiora Pharmaceuticals Inc keep up with sector leadersRisk Management & Technical Pattern Based Signals - baoquankhu1.vn
KPRXKIORA PHARMACEUTICALS INC Latest Stock News & Market Updates - Stock Titan
Retail Trends: Is Kiora Pharmaceuticals Inc a defensive stockWeekly Trend Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
What is Kiora Pharmaceuticals Inc. s debt to equity ratioIPO Watch & Community Verified Swing Trade Signals - mfd.ru
SEC EDGAR Submission 0001104659-22-079906 - SEC.gov
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - TMX Newsfile
KPRX Technical Analysis & Stock Price Forecast - Intellectia AI
KPRX PE Ratio & Valuation, Is KPRX Overvalued - Intellectia AI
Can Kiora Pharmaceuticals Inc. stock hit record highs againMarket Sentiment Summary & Entry Point Confirmation Alerts - mfd.ru
Weekly Earnings: Whats the profit margin of Kiora Pharmaceuticals IncJuly 2025 Short Interest & Weekly High Return Stock Opportunities - baoquankhu1.vn
Comparing Kiora Pharmaceuticals (NASDAQ:KPRX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN) - Defense World
Quarterly Earnings: Can MicroSectors Gold Miners 3X Leveraged ETNs due June 29 2040 continue delivering strong returnsTrend Reversal & Target Return Focused Picks - baoquankhu1.vn
Volatility Watch: Is Kiora Pharmaceuticals Inc a defensive stockBond Market & Daily Entry Point Trade Alerts - baoquankhu1.vn
Is Kiora Pharmaceuticals Inc still a buy after recent gains2025 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Kiora Pharmaceuticals adds retina specialist to advisory board By Investing.com - Investing.com Canada
Why a leading retinal surgeon is backing new non-steroid eye drugs - Stock Titan
Update Recap: Does Kiora Pharmaceuticals Inc have pricing power2025 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Trade Recap: Does Kiora Pharmaceuticals Inc have consistent dividend growthMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Can Kiora Pharmaceuticals Inc. stock surprise with earnings upsideDividend Aristocrats List & Outperform With Our Smart Trading Calculator - Bollywood Helpline
Institution Moves: Can ADS TEC Energy PLC Equity Warrant deliver alphaEarnings Growth Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Fund Flows: Is Kiora Pharmaceuticals Inc stock supported by innovation pipeline2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - Bộ Nội Vụ
Will Kiora Pharmaceuticals Inc. stock deliver better than expected guidanceMarket Movers & Weekly Stock Performance Updates - Улправда
Will Kiora Pharmaceuticals Inc. (7EY) stock announce a stock splitTrade Ideas & Risk Controlled Daily Plans - Улправда
Why Kiora Pharmaceuticals Inc. (7EY) stock trades below fair valueJuly 2025 Closing Moves & Weekly Market Pulse Updates - Улправда
Is Kiora Pharmaceuticals Inc. stock supported by strong fundamentalsWeekly Trend Recap & Weekly Consistent Profit Watchlists - ulpravda.ru
Kiora Pharmaceuticals, Inc.Common Stock (NQ: KPRX - FinancialContent
Pyxis Oncology (NASDAQ:PYXS) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Contrast - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.5% Higher – What’s Next? - Defense World
Kiora Pharmaceuticals (KPRX) Stock Analysis Report | Financials & Insights - Benzinga Italia
Aug Intraday: What momentum indicators show for CALX stockPortfolio Gains Summary & Fast Gain Stock Tips - moha.gov.vn
Will Kiora Pharmaceuticals Inc. stock reach all time highs in 2025Weekly Trade Review & Target Return Focused Stock Picks - Улправда
Is Kiora Pharmaceuticals Inc. stock a defensive play in 2025Weekly Stock Analysis & Free Risk Controlled Daily Trade Plans - Улправда
Will Kiora Pharmaceuticals Inc. stock rally after Fed decisionsJuly 2025 EndofMonth & Weekly Return Optimization Plans - Улправда
Is Kiora Pharmaceuticals Inc. stock overvalued by current metrics2025 Stock Rankings & Verified Momentum Stock Ideas - Улправда
How Kiora Pharmaceuticals Inc. stock reacts to bond yields2025 Volatility Report & Safe Entry Trade Reports - DonanımHaber
Why analysts upgrade Kiora Pharmaceuticals Inc. stockJuly 2025 Action & Free High Accuracy Swing Entry Alerts - Улправда
How Kiora Pharmaceuticals Inc. stock benefits from global expansionStock Surge & Free Growth Oriented Trading Recommendations - DonanımHaber
Can Kiora Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - Улправда
Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website - TMX Newsfile
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - TMX Newsfile
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study - TMX Newsfile
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years - TMX Newsfile
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million - TMX Newsfile
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini - TMX Newsfile
Aug Decliners: Is Kiora Pharmaceuticals Inc. stock a defensive play in 2025Swing Trade & Intraday High Probability Alerts - Улправда
The Biotech Tug-of-War: Is Kiora Pharmaceuticals Positioned to Ride the 2025 Commodity Wave? - FinancialContent
Kiora Pharmaceuticals Earnings Notes - Trefis
Aug Rallies: How geopolitical tensions affect Kiora Pharmaceuticals Inc stock2025 Bull vs Bear & Community Consensus Trade Signals - moha.gov.vn
Kiora Pharmaceuticals, Inc. (KPRX) AI-Powered Stock Analysis - Meyka
Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):